

## Announcement of CEO Appointment

28 June 2022

### Release authorised by:

The Board of TALi Digital Limited

TALi Health is delighted to announce that Dr Mary Beth Brinson has been appointed as the CEO of TALi Health. Dr Brinson was appointed as Chief Medical Officer earlier this year, however due to her broad experience and business capabilities, we feel that Dr Brinson is the right person for the CEO role. We are pleased she has accepted, and her appointment is effective immediately.

*"I am very pleased to accept the role of CEO at TALi Health. The opportunity to help children with chronic attention issues using digital therapeutics is an important one. I am looking forward to achieving this goal with TALi Health." Dr Brinson commented.*

Dr Brinson was former Vice President, Global Clinical Affairs, with medical devices leader Cochlear Limited (ASX: COH). She holds a Doctorate in Audiology from the University of Louisville in Kentucky, a Master of Business Administration from Rutgers University in New Jersey and a bachelor's degree in Audiology and Speech Pathology from the University of Georgia in the United States.

Mary Beth has held several senior roles during a 16-year career at Cochlear including Director of Quality, Clinical and Regulatory Services and Director of Clinical Services, Research and Professional Training. She is a qualified Audiologist and has practiced in healthcare and academia in the U.S. and United Kingdom. She is also an Adjunct Fellow at Macquarie University in Sydney.

Her appointment in this new role takes effect 27<sup>th</sup> June 2022. The remuneration details are outlined below.

Terms and conditions of Dr Brinson appointment as CEO

- Appointment effective immediately
- Total remuneration package of \$310,000 per annum (base salary) exclusive of superannuation.
- Short term incentive (STI) – eligible for a bonus up to 35% of base salary payable at the Boards discretion upon achievement of mutually agreed key performance indicators (KPI's)
- Long term incentive (LTI) – eligible for the shareholder approved Employee Share Option Plan (ESOP)
- Both Dr Brinson and the Company are required to provide four weeks notice of resignation or termination respectively

**CONTACT****Corporate**

Sue MacLeman  
Chair  
TALi Digital  
1300 082 013  
investors@talidigital.com

**Investors**

Dr Mary Beth Brinson  
CEO  
TALi Digital  
1300 082 013  
investors@talidigital.com

**About TALi Digital**

TALi Digital Limited (ASX: TD1) is a digital health company delivering diagnostic and therapeutic solutions to enhance cognitive function and behaviour. The Company has built a patented platform technology with our first solution targeting cognitive attention skills during early childhood via the evidence-based screening (DETECT®) and training (TRAIN®) modules. This program is complementary to existing diagnosis and therapy, placing TALi at the forefront of improving early intervention for childhood attention and concentration performance. We believe in healthy, happier minds – our vision is to deliver a personalised digital experience to enhance cognitive care.

A continuous innovation focus will see the Company deliver a series of product developments in ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder). Learn more at [talidigital.com](http://talidigital.com).